Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
Cyclerion Therapeutics (Nasdaq: CYCN) announced its management will attend the Jefferies London Healthcare Conference from Nov. 16-18, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cyclerion Therapeutics (Nasdaq: CYCN) announced its management will attend the Jefferies London Healthcare Conference from Nov. 16-18, 2021. A pre-recorded presentation will be available on-demand starting Nov. 18 for 30 days on their investor website. Cyclerion focuses on developing treatments for cognitive function, with their leading compound, CY6463, showing promise in clinical trials for various CNS diseases, including Alzheimer's Disease with vascular pathology. They are also advancing another compound, CY3018.
Details
News Market Reaction – CYCN
The recorded move for CYCN in the trading session of this news was +1.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on Nov. 16th to 18th, 2021. A pre-recorded corporate presentation will be available on-demand beginning on Thursday, Nov. 18 and will remain available for 30 days in the investor section of the Cyclerion website. Management will be available for one-on-one meetings and investors may request a meeting through Jefferies.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463, has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS), and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next-generation sGC stimulator.
For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).
Investors
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.